RecruitingNCT02760238

Myeloproliferative Neoplasms (MPNs) Patient Registry

Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs)

Sponsor

University Health Network, Toronto

Enrollment

5,000 participants

Start Date

Apr 1, 2015

Study Type

OBSERVATIONAL

Conditions

Neoplasms Mastocytosis Polycythemia Vera Primary Myelofibrosis Essential Thrombocythemia Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Leukemia, Myelomonocytic, Juvenile Chronic Eosinophilic Leukemia-not Otherwise Specified Myelodysplastic-Myeloproliferative Diseases Leukemia, Myelomonocytic, Chronic

Summary

The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.

Eligibility

Inclusion Criteria13

Diagnosis of one of the following myeloproliferative neoplasms (MPNs):
Atypical CML (aCML)
Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS),
Chronic myelomonocytic leukemia (CMML)
Chronic neutrophilic leukemia (CNL),
Essential thrombocythemia (ET),
Juvenile myelomonocytic leukemia (JMML),
Mastocytosis, MPN unclassifiable
MPN/MDS unclassifiable,
Primary myelofibrosis (PMF),
Post-essential thrombocythemia myelofibrosis (post-ET MF),
Post-polycythemia vera MF (post-PV MF)
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T)

Exclusion Criteria1

None

Interventions

OTHERObservational

Locations(1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02760238

Related Trials

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT071917301 location

Anatomical-Clinical Base of Adenocarcinoma Pancreatic

NCT061283438 locations

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

NCT042821871 location

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NCT074696831 location

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

NCT070335984 locations